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SUMMARY
In this study, the epidemiological and clinical features observed in solely HTLV-II-infected individuals were compared to
those in patients co-infected with HIV-1. A total of 380 subjects attended at the HTLV Out-Patient Clinic in the Institute of
Infectious Diseases “Emilio Ribas” (IIER), São Paulo, Brazil, were evaluated every 3-6 months for the last seven years by infectious
disease specialists and neurologists. Using a testing algorithm that employs the enzyme immuno assay, Western Blot and polymerase
chain reaction, it was found that 201 (53%) were HTLV-I positive and 50 (13%) were infected with HTLV-II. Thirty-seven (74%)
of the HTLV-II reactors were co-infected with HIV-1. Of the 13 (26%) solely HTLV-II-infected subjects, urinary tract infection
was diagnosed in three (23%), one case of skin vasculitis (8%) and two cases of lumbar pain and erectile dysfunction (15%), but
none myelopathy case was observed. Among 37 co-infected with HIV-1, four cases (10%) presented with tropical spastic paraparesis/
HTLV-associated myelopathy (TSP/HAM) simile. Two patients showed paraparesis as the initial symptom, two cases first presented
with vesical and erectile disturbances, peripheral neuropathies were observed in other five patients (13%), and seven (19%)
patients showed some neurological signal or symptoms, most of them with lumbar pain (five cases). The results obtained suggest
that neurological manifestations may be more frequent in HTLV-II/HIV-1-infected subjects than those infected with HTLV-II only.
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INTRODUCTION
Human T cell lymphotropic virus type 2 (HTLV-II) shares 65% of
its nucleotide sequences with human T cell lymphotropic virus type 1
(HTLV-I)12. HTLV-II has not been etiologically linked with any disease,
although a number of case reports and a few cross-sectional studies
suggest an association with a tropical spastic paraparesis/HTLV-
associated myelopathy (TSP)-like syndrome4,17. In addition, other
manifestations such as pneumonia, bronchitis and urinary tract infection
have been associated to HTLV-II infection18.
HTLV-II infection is presented among intravenous drug users (IDU),
HIV-1-infected patients, and some Amerindian tribes1. As HIV-1 and
HTLV-II share similar routes of transmission, mainly sexual and
intravenous drug use, and several individuals may harbor the two viruses
at the same time6,10. In Brazil, HTLV-II infection may account for 10%
of the HIV-infected population, usually the IDU in urban areas2,9. More
recently, HTLV-II infection can be found in HCV infected subjects20.
No observational studies of neurological manifestation either in HTLV-
II or co-infected with HIV-1-infected individuals have been related in
São Paulo, Brazil. In this study, four cases of myelopathy in HTLV-II/
HIV-1 co-infected subjects were described.
MATERIAL AND METHODS
A total of 380 individuals referred to the HTLV Out-Patient Clinic
at the Institute of Infectious Diseases “Emílio Ribas” (IIER) from June
1997 to June 2004 were evaluated every 3-6 months. HTLV-I or -II
infection was detected by enzyme immunoassay (HTLV-I and HTLV-
Il capture EIA, Ortho Diagnostics System Inc. Raritan, NJ, USA) and
confirmed and typed by Western-Blot (WB HTLV 2.4, GeneLabs
Diagnostics, Singapore) and/or polymerase chain reaction (PCR) for
pol region. Both assays were done in accordance with standard
protocol22. The HCV diagnosis was done by serological tests and
confirmed by qualitative PCR, both performed in the clinical routine
laboratory.
Lymphocyte T cell counts were measured by flow cytometry (XL
Model, Beckman Coulter, Inc., Fullerton, California, USA). Following
written informed consent, patients underwent a neurological evaluation
by a neurologist, who was blinded to the HTLV status of the patients.
Patients who have at least two pyramidal signs, such as paresis,
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hypertonicity or spasticity, hyperreflexia, clonus, diminished or absent
superficial reflexes, or the presence of pathological reflexes (e.g.,
Babinsky, Hoffmann, or Trömner signals), were diagnosed as having
myelopathy. It was excluded potential differential diagnosis such B12
deficiency, syphilis, thyroid dysfunction, or spinal cord compression18.
Incapacity and functional disability scale (FDS), from a modified
Kurtzke Disability Status Scale (EDSS) was used to grade the severity
of motor symptoms of myelopathy3.
In the first visit, a signed informed consent was obtained from all
participants and a personal interview was performed to fill up a
questionnaire. Every visit, one clinical and physical examination was
done, and all informations were included in the database (Epi-Info,
version 6.4). The statistical analysis was done using statistical Cal
software and the chi-square was calculated by Fisher´s exact test or by
Kruskal-Wallis´ test and the p value was considered significant when
< 0.05, two-sided.
RESULTS
Two hundred one (53%) of the 380 subjects were HTLV-I-infected
and 50 (13%) were HTLV-II infected. Thirty-seven (74%) of the HTLV-
II-infected subjects were also co-infected with HIV-1. In the 13 (26%)
solely HTLV-II-infected subjects (nine women and four men), the mean
age was 38 ± 12 years, the major risk for HTLV-II group was sexual
risk, only two cases were IDU (p = 0.0005, Fisher´s exact test). Among
the 50 co-infected patients, 26 (70%) were males, and 28 (76%) were
IDU. Similarly, HCV infection was more likely to occur in the co-
infected group (p = 0.005, Fisher´s exact test). As expected, the CD4+
T cell counts were lower in the HTLV-II/HIV-1 co-infected subjects (p
= 0.01, Kruskal-Wallis´ test). Demographical, laboratorial, and clinical
data of the HTLV-II-infected cases are summarized in Table 1.
Among 13 solely HTLV-II-infected subjects, urinary tract infection
was diagnosed in three (26%) and there was one (8%) case of skin
vasculitis. Two patients presented with lumbar pain and erectile
dysfunction (15%). No myelopathy case was observed. In contrast,
among the 37 co-infected with HIV-1, four (10%) cases presented with
TSP/HAM simile. Two of them showed paraparesis as the initial
symptom and the other two initially presented with vesical and erectile
disturbances. Peripheral neuropathies were observed in five patients
(13%). Other seven (19%) patients showed some neurological signals
or symptoms, mostly lumbar pain (five cases).
The four TSP/HAM co-infected HIV-1/HTLV-II cases are presented
below:
Patient 1: A 54-year-old homosexual male who presented
neurological symptoms in April 1997, when he showed reactivity for
HIV-1 antibodies. He denied any symptoms before that occasion. He
had progressive walking impairment, with wheelchair outcome in June
1997, along with urinary and impotence disturbances. In July, because
of his CD4+ T cell count (271 cells/mm3), he was started on antiretroviral
therapy (ARV therapy) with zidovudine (AZT), lamivudina (3TC), and
ritonavir. After three months of ARV therapy, he recovered from urinary
symptoms and he could walk with a walker. At this time, his CD4+ T
cell count was 267 cells/mm3 and HIV-1 RNA load was 45,000 copies/
mL. Nine months later, he was able to walk independently and there
was a slight bladder dysfunction (FDS from 5 to 2). Even though he
was seronegative for HTLV antibodies, the PCR for HTLV-II was
positive on two different occasions.
Patient 2: 33 year-old male, an ex-IDU who was found to have an
HIV-1-infection in 1997. On this occasion, he had difficulties for
walking, with wheelchair outcome in October 97, when he started with
AZT, 3TC and indinavir. In March 98, at the first neurological
evaluation, he was able to walk with a walker. After 18 months of ARV
he was able to walk with a cane (FDS from 5 to 3), and the CD4+ T cell
count rose from 01 cell to 771 cells/mm3 and the RNA viral load
decreased from 130,000 copies/mL to less than 80 copies/mL in October
1999. Both WB and PCR revealed HTLV-II infection.
Patient 3: a 31 year-old male, was an ex-IDU, with HIV-1 and
HCV infections. He showed clinical features of TSP/HAM in 2001,
including sexual dysfunction erection. His CD4+ T cell count was 677
in 2000 with a viral load of less than 400 copies/mL. He never used
ARV and has been asymptomatic for HIV and HCV infections.
Unfortunately, his follow up was lost. The WB profile revealed HTLV-
II infection.
Patient 4: a 38-year-old ex-IDU male, who was infected with HIV-
1, HCV and HTLV-II. He developed TSP/HAM-like symptoms (it may
Table 1
Demographic, laboratorial and clinical data of 50 human T-cell lymphotropic virus type 2 (HTLV-II)-infected subjects at the baseline, evaluated at HTLV Out-Patient
Clinic of Infectious Diseases Institute, São Paulo City, SP, Brazil, from June 1997 to June 2004
Variable HTLV-II-infected solely HTLV-II/HIV-1- co-infected p value
(n = 13) (n = 37)
Gender ratio (M/F)* 4/9 26/11 0.03*
Age (Mean ± SD)/years* 38 ± 12 36 ± 8 0.09*
IDU risk n (%)* 2 (15) 28 (76) 0.0005*
HCV n (%)* 2 (15) 24 (65) 0.006*
CD4+ T (cells/mm3)** (mean ± SD) 1003 ± 376 417 ± 369 < 0.01**
CD8+ T (cells/mm3)** (mean ± SD) 535 ± 215 897 ± 537 0.004**
Myelopathy 0 4 0.5*
*Fisher´s exact test; ** Kruskal-Wallis´ test; M = male; F = Female; SD = Standard deviation; IDU: intravenous drug user; HCV = hepatitis C virus.
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be vacuolar myelopathy) in March 2001. His incapacity scale was seven,
and his follow up was lost. HTLV-II infection was observed in the WB
profile and PCR.
DISCUSSION
HTLV-II-infection was more common in women (2:1 ratio) among
HIV-uninfected subjects. Whereas, this infection was more frequently
in males during the co-infection with HIV-1. This finding can be
explained by the high prevalence of HCV co-infection with HIV in
IDU (~70%), in contrast in solely HTLV-II-infected subjects, where
only ~20% with anti-HCV antibodies were found. These observations
probably reflect the routes of transmissions, since among women, the
major route for HTLV-II infection was heterosexual partner relationship
or being Indians descendents, and among the HIV-1-infected subjects
were basically IDU (data not shown). Taken together, these data indicate
that use of intravenous drug is the most potential mode of transmission
of these viruses. The high co-existence of HTLV-II and HCV in this
host may have important clinical and epidemiological implications in
this population. New evidences show that HTLV-II/HIV-1 coinfection
may be harmful for the host. In fact, the role of HTLV-II infection
interaction with HCV on liver damage should be better investigated
since HTLV-I/HCV patients present worse prognosis for cirrhosis and
hepatocarcinoma8 or higher HCV viral load11.
The CD4+ and CD8+ T cells counts in the single HTLV-II infection
were normal; in contrast, in the HIV-1/HTLV-II co-infected group, CD4+
T cell counts were lower and the CD8+ T cell count were higher. These
findings may reflect the immune pathogenesis of HIV-1-infection,
where HIV leads to CD4+ T cells destruction and the immune activation
causes increasing of CD8+ T cells during infection. On basis of the
clinical findings, some HTLV-II-infected subjects showed peripheral
neuropathy during the co-infection and urinary tract infection either in
HIV-1/HTLV-II-infected subjects as well in solely infected with HTLV-
II. These findings have been shown by other investigators2,23, but its
pathogenesis remain to be better studied.
Risk for TSP/HAM development is less than 1% after decades of
incubation period among the HTLV-I-infected individuals13. It has been
described that HTLV-II also may account for some unique cases14,16,18,21.
Thus, the cases reported in this study may represent a common feature
in the HIV/AIDS epidemic in countries where these two retroviruses
are highly endemic, as is the case of Brazil. In fact, the high prevalence
was first described in developed countries5. In addition, only one case
of vacuolar myelopathy was diagnosed in the last years among single
HIV-1-infected subjects in a cohort of 240 HIV-infected subjects who
have been followed up at the Hospital das Clinicas in São Paulo city
since 1989 (data not shown).
Despite no TSP/HAM simile case or other neurological syndromes
were observed on solely HTLV-II infection in the cohort evaluated in
this study, other groups in South America have described such
cases6,7,15,21. There are some clinical and laboratorial data that suggest
that HTLV-II infection induces the myelopathy process during co-
infection with HIV-15, since the major differential diagnosis should be
done with vacuolar myelopathy19. Despite that, only spinal cord
histological findings could be addressed in this issue, usually vacuolar
myelopathy in HIV-1-infected patients may occur without cognitive
damage (dementia) and low CD4+ T cell count19. It was noted that
clinical improvement of TSP/HAM symptoms after ARV and this
finding deserves further investigation. Furthermore, other etiologies
should be ruled out such as infections, expansive lesions, vitamin B12
deficiency and other metabolic disturbances.
RESUMO
Aspectos clínicos e epidemiológicos da infecção pelo vírus
linfotrópico de células T humanas do tipo 2 (HTLV-II) em São
Paulo, Brasil: presença de paraparesia espástica tropical/
mielopatia associada ao HTLV em pacientes
co-infectados pelo HIV-1
Neste estudo, as características epidemiológicas e clínicas
observadas nos indivíduos infectados pelo HTLV-II foram comparadas
com os pacientes co-infectados com HIV-1. Um total de 380 indivíduos
atendidos na clínica do Ambulatório HTLV do Instituto de Infectologia
“Emilio Ribas” (IIER), São Paulo, Brasil, foram avaliados a cada 3-6
meses nos últimos sete anos por especialistas em doenças infecciosas
e neurologistas. Usando um algoritmo que emprega ensaio
imunoenzimático, Western Blot e reação em cadeia de polimerase,
foram incluídos 201 (53%) pacientes infectados pelo HTLV-I e 50
(13%) infectados pelo HTLV-II. Trinta e sete (74%) eram co-infectados
pelo HTLV-II e HIV-1. Dos 13 (26%) indivíduos unicamente infectados
pelo HTLV-II, infecção do trato urinário foi diagnosticada em três, um
com vasculite e em dois casos dor lombar e disfunção erétil mas nenhum
caso de mielopatia foi observado. Entre 37 pacientes co-infectados
com HIV-1, quatro (10%) casos apresentaram com paraparesia espástica
tropical/mielopatia associada ao HTLV similar. Dois casos mostraram
paraparesia como sintoma inicial, dois outros casos se apresentaram
primeiramente com distúrbios vesical e erétil e as neuropatias
periféricas foram observadas em cinco pacientes (13%). Outros sete
(19%) pacientes mostraram algum sinal ou sintoma neurológico, a
maioria deles com dor lombar (cinco casos). Os resultados sugerem
que as manifestações neurológicas podem ser mais freqüentes em
indivíduos co-infectados pelo HTLV-II/HIV-1 do que nos indivíduos
infectados somente pelo HTLV-II.
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